Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day DOI Creative Commons
Eugene A. Kiyatkin

F1000Research, Год журнала: 2022, Номер 10, С. 477 - 477

Опубликована: Фев. 2, 2022

Background. Various in vitro studies have shown fluoxetine inhibits multiple variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen causing disease 2019 (COVID-19) worldwide pandemic and observational clinical that patients receiving experienced benefit by lowering risk intubation death. The aim this study is to conduct population pharmacokinetic dosing simulations quantify percentage achieving a trough level for effective concentration resulting in 50% (EC50) 90% (EC90) inhibition SARS-CoV-2 as reported Calu-3 human lung cells. Methods. Pharmacometric parameter estimates used were obtained from U.S. FDA website new drug application hydrochloride. A 1,000 individuals simulated at standard antidepressant doses (20 mg/day, 30 40 50 60 mg/day) estimate plasma EC50 EC90 inhibition. All analyses graphing conducted R. Results. By day-10 20 mg/day 93.2% 47% will achieve target concentrations, respectively, which translates tissue distribution coefficient 60-times higher (283.6 ng/ml [0.82 mM]) (1390.1 [4.02 mM]). Further, an ideal dose 99% 93% reach respectfully. Lastly, only inhibitory brain. Conclusion. Overall, with minimum treatment period 10-days corroborates reporting inhibiting titers also observational showing therapeutic COVID-19 patients.

Язык: Английский

Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution DOI Creative Commons
Milica Borovčanin, Katarina Vesić, Yasin Hasan Balcıoğlu

и другие.

Frontiers in Psychiatry, Год журнала: 2022, Номер 13

Опубликована: Окт. 19, 2022

OPINION article Front. Psychiatry, 19 October 2022Sec. Molecular Psychiatry Volume 13 - 2022 | https://doi.org/10.3389/fpsyt.2022.1052710

Язык: Английский

Процитировано

7
Antipsychotic use and 28-day mortality in patients hospitalized with COVID-19: A multicenter observational retrospective study DOI Creative Commons
Marina Sánchez‐Rico,

Alejandro Edán-Sánchez,

Mark Olfson

и другие.

European Neuropsychopharmacology, Год журнала: 2023, Номер 75, С. 93 - 104

Опубликована: Июнь 16, 2023

Язык: Английский

Процитировано

4
Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update DOI
Udo Bonnet, Georg Juckel

Fortschritte der Neurologie · Psychiatrie, Год журнала: 2024, Номер unknown

Опубликована: Сен. 23, 2024

Introduction Preclinically, fluvoxamine and other antidepressants (AD) exerted antiviral anti-inflammatory properties also against SARS-COV-2. Therfore, It makes sense to test the clinical effect of AD COVID-19 Long COVID.

Язык: Английский

Процитировано

1
Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection DOI Creative Commons
Pascal Le Corre, Gwenolé Loas

Frontiers in Pharmacology, Год журнала: 2022, Номер 13

Опубликована: Март 3, 2022

The rapid spread of COVID-19 has become a health emergency causing an urgent need for drug treatments to control the outbreak, especially in more vulnerable individuals. This is reinforced by fact that prophylactic vaccines and neutralizing monoclonal antibodies may not be fully effective against emerging variants. Despite all efforts made scientific community, efficient therapeutic options currently remain scarce, either initial, as well advanced forms disease. From retrospective observational studies prospective clinical trials, selective serotonin reuptake inhibitors (SSRIs), other antidepressants with functional inhibition acid sphingomyelinase (FIASMAs), have emerged potential COVID-19. led some prematurely optimistic points view, promoting large prescription fluvoxamine patients COVID-19, we think should reasonably tempered.

Язык: Английский

Процитировано

6
Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day DOI Creative Commons
Eugene A. Kiyatkin

F1000Research, Год журнала: 2022, Номер 10, С. 477 - 477

Опубликована: Фев. 2, 2022

Background. Various in vitro studies have shown fluoxetine inhibits multiple variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen causing disease 2019 (COVID-19) worldwide pandemic and observational clinical that patients receiving experienced benefit by lowering risk intubation death. The aim this study is to conduct population pharmacokinetic dosing simulations quantify percentage achieving a trough level for effective concentration resulting in 50% (EC50) 90% (EC90) inhibition SARS-CoV-2 as reported Calu-3 human lung cells. Methods. Pharmacometric parameter estimates used were obtained from U.S. FDA website new drug application hydrochloride. A 1,000 individuals simulated at standard antidepressant doses (20 mg/day, 30 40 50 60 mg/day) estimate plasma EC50 EC90 inhibition. All analyses graphing conducted R. Results. By day-10 20 mg/day 93.2% 47% will achieve target concentrations, respectively, which translates tissue distribution coefficient 60-times higher (283.6 ng/ml [0.82 mM]) (1390.1 [4.02 mM]). Further, an ideal dose 99% 93% reach respectfully. Lastly, only inhibitory brain. Conclusion. Overall, with minimum treatment period 10-days corroborates reporting inhibiting titers also observational showing therapeutic COVID-19 patients.

Язык: Английский

Процитировано

5